Oncologic Outcome of Robotic-Assisted and Laparoscopic Sentinel Node Biopsy in Endometrial Cancer.

Simple Summary: In our study of 419 patients with endometrial cancer, we looked at two ways of checking the spread of the disease: one called 'sentinel lymph node biopsy' (SLNB) and the other, a more traditional method called 'lymph node dissection' (LND). We followed these patients for about 5.5 years. We found that both methods had similar outcomes in terms of how long patients lived without the disease coming back (known as disease-free survival) and how long they lived overall (overall survival). Whether patients had their complete lymph nodes checked or only the sentinel did not seem to change how well they did. But we did notice that the kind of treatment they received afterward could affect how they did. Overall, it seems like the newer SLNB method is just as good as the traditional LND in helping patients with endometrial cancer. Background: Recently, sentinel lymph node biopsy (SLNB) has been introduced in the surgical staging of endometrial cancer as an alternative to systematic lymph node dissection (LND). However, the survival impact of SLNB is not yet well characterised. Methods: We performed a retrospective study of 419 patients with endometrial cancer treated with SLNB alone or with pelvic and para-aortic LND. For SLNB mapping, indocyanine green was used. Results: Median follow-up was 66 months. After exclusions, 337 patients were eligible for analysis. Of them, 150 underwent SLNB and 187 LND. During the follow-up time, 27 (24.7%) of the 150 who underwent SLNB and 54 (28.9%) of the 187 who underwent LND were diagnosed with recurrent disease (p = 0.459). The estimated 5-year disease-free survival (DFS) rate was 76.7% and 72.2% for patients in the SLNB and LND group, respectively (p = 0.419). The 5-year overall survival (OS) rates were 80.7% and 77.0% in the SLNB and LND group, respectively (p = 0.895). Survival rates were similar in both groups independent of lymph node status. Multivariable analysis confirmed that the staging approach was not associated with oncological outcome. For patients without lymph node metastases, patient outcome was worsened by advanced tumour stage and non-endometrioid tumour histology. In the group of patients with confirmed lymph node metastases, advanced tumour stage and inadequate adjuvant treatment significantly reduced DFS and OS. Conclusion: Our data suggested that SLNB did not compromise the oncological outcome of patients with endometrial cancer compared to LND. [ABSTRACT FROM AUTHOR]